Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 70-75

  Muramatsu, Hideaki ^a   Horii, Toshinobu ^a   Takeshita, Akihiro ^a   Hashimoto, Hisakuni ^a   Maekawa, Masato ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbapenems; Fluoroquinolones; GyrA; GyrB; OprD; ParC

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM DERIVATIVE; CEFCAPENE; CEFDINIR; CEFEPIME; CEFOTIAM; CEFOZOPRAN; CEFPIROME; CEFSULODIN; CEFTAZIDIME; COTRIMOXAZOLE; FLEROXACIN; FLOMOXEF; FROPENEM; GATIFLOXACIN; GLUTAMIC ACID; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NORFLOXACIN; PANIPENEM; PAZUFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SITAFLOXACIN; SPARFLOXACIN; THREONINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 22144441408     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085612     Document Type: Article

References (27)

1. Kocazeybek BS: Antimicrobial resistance surveillance of gram-negative bacteria isolated from intensive care units of four different hospitals in Turkey. Evaluation of the prevalence of extended-spectrum and inducible β-lactamases using different E-test strips and direct induction methods. Chemotherapy 2001;47:396-408.
2. Rodriguez AJ, Samaniego DR, Soskin A, Rodriguez CN, Canese J, de Canese JO, Molina N, Garcia A, Duque C, Meijomil P, Arena F: Comparative study of antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients of Caracas and Asuncion in a 4-year-period. Chemotherapy 2002;48:164-167.
3. Erdem I, Kucukercan M, Ceran N: In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 2003;49:294-297.
4. Fish DN, Piscitelli SC, Danziger LH: Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995;15:279-291.
5. Hancock RE: Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998;27(suppl 1):S93-S99.
6. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E: In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001;48:553-555.
7. Akasaka T, Tanaka M, Yamaguchi A, Sato K: Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001;45:2263-2268.
8. Mouneimné H, Robert J, Jarlier V, Cambau E: Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:62-66.
9. Jalal S, Wretlind B: Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998;4:257-261.
10. Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002;34:634-640.
11. Takenouchi T, Sakagawa E, Sugawara M: Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob Agents Chemother 1999;43:406-409.
12. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 5. Approved Standard M7-A4. Wayne, NCCLS, 2000.
13. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989.
14. Horii T, Yokoyama K, Barua S, Odagiri T, Futamura N, Hasegawa T, Ohta M: The staphylokinase gene is located in the structural gene coding for N-acetylmuramyl-L-alanine amidase in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2000;185:221-224.
15. MOX-1 gene encoding AmpC-type β-lactamase. Gene 1994;139:93-98.
16. Muramatsu H, Horii T, Morita M, Hashimoto H, Kanno T, Maekawa M: Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates. Int J Med Microbiol 2003;293:191-197.
17. Horii T, Muramatsu H, Morita M, Maekawa M: Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy. Microb Drug Resist 2003;9:223-229.
18. Yonezawa M, Takahata M, Matsubara N, Watanabe Y, Narita H: DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:1970-1972.
19. Nakano M, Deguchi T, Kawamura T, Yasuda M, Kimura M, Okano Y, Kawada Y: Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41:2289-2291.
20. Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V: Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 1995;39:2248-2252.
21. IMP. Antimicrob Agents Chemother 1998;42:2006-2011.
22. Studemeister AE, Quinn JP: Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob Agents Chemother 1998;42:1267-1268.
23. Livermore DM: Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-250.
24. Lodge JM, Minchin SD, Piddock LJV, Busby SJ: Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC β-lactamase. Biochem J 1990;272:627-631
25. Hazumi N, Fuse A, Matsuda K, Hashizume T, Sanada M: Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-β-methyl carbapenem. Antimicrob Agents Chemother 1995;39:702-706.
26. Amari EBE, Chamot E, Auckenthaler R, Pechère JC, van Delden C: Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859-1864.
27. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann M-C: Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340-345.